Key terms
About CABA
Cabaletta Bio, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in April 2017 and is headquartered in Philadelphia, PA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest CABA news
Apr 04
6:23am ET
Cabaletta Bio price target raised to $30 from $26 at Citi
Apr 04
5:20am ET
Analysts Offer Insights on Healthcare Companies: Alcon (ALC) and Cabaletta Bio (CABA)
Mar 25
10:10pm ET
Analysts Offer Insights on Healthcare Companies: AbSci (ABSI), HilleVax, Inc (HLVX) and Cabaletta Bio (CABA)
Mar 25
9:02am ET
Cabaletta Bio price target raised to $33 from $31 at Morgan Stanley
Mar 22
6:33am ET
Cabaletta Bio price target lowered to $34 from $35 at Wells Fargo
Mar 22
6:15am ET
Strong Buy on Cabaletta Bio: Promising CAR T Candidate and Robust Financial Outlook
Mar 22
6:06am ET
Cabaletta Bio price target raised to $30 from $25 at H.C. Wainwright
Mar 22
5:18am ET
Wells Fargo Releases a Buy Rating on Cabaletta Bio (CABA)
Mar 21
1:45pm ET
Cabaletta Bio Earns ‘Buy’ Rating on Clinical Progress and Strong Financials
Mar 21
1:07pm ET
Cabaletta Bio price target raised to $32 from $31 at Stifel
Mar 21
1:05pm ET
Cabaletta Bio Earns ‘Buy’ Rating on Impressive Clinical Progress and Strategic Market Positioning
Mar 21
11:35am ET
Cabaletta Bio (CABA) Gets a Buy from TD Cowen
Mar 21
8:06am ET
Cabaletta Bio files automatic mixed securities shelf
Mar 21
7:08am ET
Cabaletta Bio reports Q4 EPS (46c), consensus (39c)
Mar 20
7:22am ET
Cabaletta Bio Receives Orphan Drug Status for CABA-201
Mar 20
7:02am ET
Cabaletta Bio granted Orphan Drug designation to CABA-201
Mar 19
1:47pm ET
Cabaletta Bio treatment of systemic sclerosis granted orphan designation
Feb 05
4:34am ET
Cabaletta Bio initiated with a Buy at Jefferies
Feb 05
3:55am ET
Strong Buy Rating for Cabaletta Bio Amid Positive CART Therapy Prospects and Market Potential
Feb 01
4:34pm ET
Cabaletta: FDA grants ODD to CABA-201 for myositis treatment
Jan 31
6:17pm ET
Cabaletta Bio treatment of IIM granted FDA orphan designation
Jan 22
4:40pm ET
FDA instructs drugmakers to add T cell malignancy risk info to CAR-T labels
Jan 08
11:05am ET
Biotech Alert: Searches spiking for these stocks today
Jan 08
7:20am ET
Cabaletta Bio receives additional FDA Fast Track Designations for CABA-201
No recent press releases are available for CABA
CABA Financials
Key terms
Ad Feedback
CABA Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
CABA Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
